These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 36145365)

  • 1. Synthesis of Novel
    Amblard F; LeCher JC; De R; Goh SL; Li C; Kasthuri M; Biteau N; Zhou L; Tber Z; Downs-Bowen J; Zandi K; Schinazi RF
    Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
    Stegmann KM; Dickmanns A; Heinen N; Blaurock C; Karrasch T; Breithaupt A; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Herrmann ST; Schreieck A; Peelen E; Kohlhof H; Sadeghi B; Riek A; Speakman JR; Groß U; Görlich D; Vitt D; Müller T; Grunwald T; Pfaender S; Balkema-Buschmann A; Dobbelstein M
    iScience; 2022 May; 25(5):104293. PubMed ID: 35492218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of assays for the quantification of β-D-N
    Parsons TL; Kryszak LA; Marzinke MA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122921. PubMed ID: 34555541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.
    Hadj Hassine I; Ben M'hadheb M; Menéndez-Arias L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anti-SARS-CoV-2 activity of deuterated GS-441524 analogs.
    Zheng W; Hu T; Zhang Y; Wei D; Xie Y; Shen J
    Tetrahedron Lett; 2022 Aug; 104():154012. PubMed ID: 35844292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.
    Li J; Liu S; Shi J; Wang X; Xue Y; Zhu HJ
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):870-887. PubMed ID: 33855276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.